XORTX Therapeutics (XRTX) Profit After Tax (2020 - 2026)

XORTX Therapeutics (XRTX) has 7 years of Profit After Tax data on file, last reported at -$808472.0 in Q1 2026.

• Quarterly Profit After Tax fell 15.72% year-over-year to -$808472.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.1 million (down 225.5% YoY) and the FY2025 annual result came in at -$2.7 million, down 180.17% from the prior year.
• Profit After Tax improved to -$808472.0 in Q1 2026, from -$4.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $7.0 million in Q4 2023 to a low of -$4.7 million in Q4 2025.
• A 5-year average of -$564004.6 and a median of -$1.2 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 426.32% — and 2025, when it tumbled 623.29%.
• Tracing XRTX's Profit After Tax over 5 years: stood at -$2.1 million in 2022, then jumped by 426.32% to $7.0 million in 2023, then dropped by 3.79% to $6.7 million in 2024, then tumbled by 169.97% to -$4.7 million in 2025, then soared by 82.88% to -$808472.0 in 2026.
• The last three Profit After Tax figures came in at -$808472.0 (Q1 2026), -$4.7 million (Q4 2025), and -$649469.0 (Q3 2025), per Business Quant data.